Reviews in Urology Volume 23, Issue 3 2024Contents

Letter From the President of LUGPALUGPA NewsCorrected drug delivery informationProstate CancerAdvances in Radical Prostatectomy: A Narrative ReviewAustin Drysch, Kathryn E. Fink, Chalairat Suk-Ouichai, Mitchell M. Huang, Kent T. Perry, Hiten D.Patel, Ashley E. RossDarolutamide for the Management of Metastatic Hormone-Sensitive Prostate Cancer: A Urologist-Oncologist PerspectivePaul Dato, Rana R. McKayIncorporation of IsoPSA Into Clinical Practice in the Management of Elevated Prostate-Specific Antigen Based on Current GuidelinesAidan Kennedy, Jason HafronPediatric UrologyRecent Advances in Managing Pediatric Neurogenic Bladder due to Spina BifidaRachel Vancavage, Alexandra RehfussKidney CancerResponse to Targeted Therapy and Checkpoint Inhibition in a Patient With Mucinous Tubular and Spindle Cell Carcinoma: A Case Report and Literature Review
Ruchi Agarwal; Daniela V. Castro, Yu Jun Li, Jaya Goud, Salvador Jaime-CasasBladder CancerImmune Checkpoint Inhibitors for the Treatment of Non–Muscle-Invasive Bladder Cancer: An Overview of Ongoing Clinical TrialsNeal Shore, MDBusiness of UrologyThe Business of Independent Urologic Medicine: Caring for Patients While Operating a Business in a Post–COVID-19 Era of Private PracticeNathan P. Diller, Mara HoltonEditorialThe Specialty Networks Localized to High-Risk Biochemically Recurrent Prostate Cancer Patient PlaybookGautam Jayram, Katie Grant, Jayme Nalley, Nicole SmithMeet the ExpertMeet the Expert: Shelby Moneer, MS, CHES, from ZERO Prostate CancerBenjamin LowentrittCoverKEYTRUDAKEYTRUDA 2KEYTRUDA 3KEYTRUDA 4KEYTRUDA 5KEYTRUDA 6KEYTRUDA 7LUGPAJELMYTOJELMYTO 2Pfizer OncologyPfizer Oncology 2Leadership & Editorial StaffContentsLUGPA 2025Letter From the President of LUGPAPARP Resource GuideLUGPA NewsCorrectionIsoPSAAdvances in Radical Prostatectomy: A Narrative ReviewDarolutamide for the Management of Metastatic Hormone- Sensitive Prostate Cancer: A Urologist-Oncologist PerspectiveRecent Advances in Managing Pediatric Neurogenic Bladder due to Spina BifidaIncorporation of IsoPSA Into Clinical Practice in the Management of Elevated Prostate- Specific Antigen Based on Current GuidelinesResponse to Targeted Therapy and Checkpoint Inhibition in a Patient With Mucinous Tubular and Spindle Cell Carcinoma: A Case Report and Literature ReviewCiplaImmune Checkpoint Inhibitors for the Treatment of Non–Muscle-Invasive Bladder Cancer: An Overview of Ongoing Clinical TrialsThe Business of Independent Urologic Medicine: Caring for Patients While Operating a Business in a Post–COVID-19 Era of Private PracticeThe Specialty Networks Localized to High- Risk Biochemically Recurrent Prostate Cancer Patient PlaybookLocalized to High-Risk/Biochemically Recurrent Prostate CancerMeet the Expert: Shelby Moneer, MS, CHES, from ZERO Prostate CancerPPS AnalyticsWELIREGWELIREG 2WELIREG 3WELIREG 4WELIREG 5WELIREG 6Pfizer Urology Oncology